Next Article in Journal
Proline-Catalysed Amination Reactions in Cyclic Carbonate Solvents
Previous Article in Journal
N-Cyanomethylnorboldine: A New Aporphine Isolated from Alseodaphne perakensis (Lauraceae)
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 16
Issue 4
10.3390/molecules16043410
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Anticancer Activity of Some Novel Tetralin-6-yl-pyrazoline, 2-Thioxopyrimidine, 2-Oxopyridine, 2-Thioxo-pyridine and 2-Iminopyridine Derivatives

by
Ebtehal S. Al-Abdullah
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
Molecules 2011, 16(4), 3410-3419; https://doi.org/10.3390/molecules16043410
Submission received: 7 March 2011 / Revised: 29 March 2011 / Accepted: 8 April 2011 / Published: 20 April 2011
Browse Figures
Versions Notes

Abstract

:
The title compounds were prepared by reaction of 6-acetyltetralin (1) with different aromatic aldehydes 2a-c, namely 2,6-dichlorobenzaldehyde, 2,6-diflouro-benzaldehyde, and 3-ethoxy-4-hydroxybenzaldehyde, to yield the corresponding α,β-unsaturated ketones 3a-c. Compound 3b was reacted with hydrazine hydrate to yield the corresponding 2-pyrazoline 4, while compounds 3a,b reacted with thiourea to afford the 2-thioxopyrimidine derivatives 5a,b, respectively. The reaction of 1, and the aromatic aldehydes 2a-c with ethyl cyanoacetate, 2-cyano-thioacetamide or malononitrile in the presence of ammonium acetate yielded the corresponding 2-oxopyridines 6a,b, 2-thioxopyridines 7a-c or 2-iminopyridines 8a,b, respectively. The newly prepared compounds were evaluated for anticancer activity against two human tumor cell lines. Compound 3a showed the highest potency with IC50 = 3.5 and 4.5 μg/mL against a cervix carcinoma cell line (Hela) and breast carcinoma cell line (MCF7), respectively.

1. Introduction

Cancer is presently responsible for about 25% of deaths in developed countries and for 15% of all deaths worldwide. It can therefore be considered as one of the foremost health problems, with about 1.45 million new cancer cases expected yearly. Antitumor chemotherapy is nowadays a very active field of research, and a huge amount of information on the topic is generated every year [1,2]. Although there is a large amount of information available dealing with clinical aspects of cancer chemotherapy, we felt that there was a clear need for an updated treatment from the point of view of medicinal chemistry and drug design [3]. Diverse chemotherapeutic activities were ascribed to substituted tetralin (tetrahydronaphthalene)-heterocycles [4,5] and tetrahydronaphthalene derivatives, especially those incorporated into heterocyclic systems [6]. It has been reported that this type of compounds possess a wide variety of biological activities including anti-HIV [5], antibacterial [4,7], hypotensive [8], antiarrythmic [9], molluscicidal [10], antiplatelet aggregation [11,12], anxiolytic and antidepressant [13,14] and anticancer [15,16] effects. Pyridin-2(1H)-ones are known to possess a range of biological activities such as analgesic, antifungal, antimalarial, antiinflammatory, antibacterial, anti-HIV, phytotoxic, antitumoral and antiviral properties [17,18,19,20,21,22,23,24]. Thus, it was of interest to synthesize some new heterocyclic derivatives carrying a tetrahydronaphthale moiety for evaluation as potential anticancer agents.

2. Results and Discussion

2.1. Chemistry

α,β-Unsaturated ketons (chalcones) are active intermediates and excellent starting materials for the synthesis of several heterocyclic systems. Thus, a Claisen-Schmidt reaction of 1-(1,2,3,4-tetrahydro-naphthaline-6-yl)ethanone (1), prepared following the previously reported method of Allinger and Jones [25], with 2,6-dichlorobenzaldehyde (2a), 2,6-diflourobenzaldehyde (2b) or 3-ethoxy-4-hydroxybenzaldehyde (2c), in 10% ethanolic sodium hydroxide afforded the corresponding α,β-unsaturated ketons 3a-c in 53, 42 and 80% yields, respectively. Condensation of the chalcone analogue 3b with hydrazine hydrate in acetic acid yielded the corresponding 1-acetyl-2-pyrazoline derivative 4 in 92% yield. Meanwhile, the interaction of the chalcone analogues 3a,b with thiourea in aqueous potassium hydroxide yielded the corresponding 2-thioxopyrimidines 5a,b in 20 and 28% yields, respectively (Scheme 1, Table 1).
Condensation of compound 1 and the aromatic aldehydes 2a or 2b with ethyl cyanoacetate in presence of excess ammonium acetate in n-butanol afforded the corresponding 3-cyano-2-(1H)-oxopyridines 6a and 6b in a one pot reaction. Similarly, the reaction of compound 1 and the aromatic aldehydes 2a-c with 2-cyanothioacetamide yielded the corresponding 3-cyano-2-(1H)-thioxopyridines 7a-c in 25, 53 and 90% yields, respectively. The 3-cyano-2-(1H)-iminopyridines 8a and 8b were also prepared in fair yields by applying the aforementioned one pot reaction of the compound 1, the corresponding aldehyde and malononitrile (Scheme 2, Table 1). The structures of the newly synthesized compounds were confirmed on the basis of their elemental analysis and IR, 1H-NMR, 13C-NMR and mass spectral data.

2.2. Anticancer Screening

All the newly synthesized compounds were tested at the Department of Tumor Pathology, National Cancer Institute, Cairo, Egypt. Two cell lines were used for the evaluation – human cervix carcinoma cell line (Hela) and human breast carcinoma cell line (MCF7). The newly synthesized analogs 3a-c, 4, 5a,b, 6a,b, 7a-c and 8a,b were tested for in vitro cytotoxic activity against these cell lines, which were obtained frozen in liquid nitrogen (-180 °C) from the American Type Culture Collection [26]. The tumor cell lines were maintained in the National Cancer Institute, Cairo, Egypt, by serial sub-culturing.
The results (Table 2) are expressed in the form of the concentration of compound that causes 50% inhibition of cells growth. The in vitro evaluation revealed that all the newly synthesized compounds showed certain activity against tumor cell lines tested, although the activity was generally higher towards the cervical cancer line than the breast cancer one. Compound 3a showed potent and broad antitumor activity against the two tumor cell lines tested (IC50 = 3.5 against Hela and IC50 = 4.5 against MCF7) compared to the potent anticancer drug 5-flourouracil (5-FU) used as a reference standard [27]. Substitution of the side chain with different ring systems like in the oxopyridine or thioxopyridine compounds 6a,b and 7a,b resulted in moderate activity against the Hela cell line and marked activity against the MCF-7 cell line. Meanwhile, substitution of the side chain with iminopyridine, thioxopyrimidine and/or pyrazoline rings resulted in low activity against the two tumor cell lines. These results demonstrated that changing the molecular conformation and orientation could influence markedly the antitumor activity against the two tested cell types.

3. Experimental

3.1. General

Melting points (°C, uncorrected) were measured in open glass capillaries using a Barnstead 9001 electrothermal melting point apparatus. Infrared spectra (ν, cm-1) were recorded on a Jasco FT/IR-330E, Fourier Transform Infrared Spectrometer using KBr discs. 1H-NMR spectra were determined using a Bruker AC 500 Ultra Shield NMR spectrometer operating at 500.13 MHz for 1H and 125.76 MHz for 13C, the chemical shifts are expressed in δ (ppm) downfield from tetramethylsilane (TMS) used as internal standard. Electron impact mass spectra (EI-MS) were recorded on a Shimadzu GC-MS-QP 5000 instrument at 70 eV. Elemental analyses (C, H, N) were in full agreement with the proposed structures within ±0.4% of the theoretical values. Monitoring the reactions and checking the purity of the final products were carried out by thin layer chromatography (TLC) using silica gel precoated aluminum sheets (60 F254, Merck) and visualization with ultraviolet light (UV) at 365 and 254 nm.

3.2. 3-Aryl-1-(1,2,3,4-tetrahydronaphthalen-6-yl)prop-2-en-1-ones 3a-c

A mixture of 6-acetyltetraline 1 (4.9 g, 0.028 mol), the appropriate aldehyde 2a-c (0.028 mol) and 10% ethanolic sodium hydroxide solution (15 mL) in ethanol (30 mL) was stirred for 12 h. The reaction mixture was then warmed at 40 °C for 10 min. and the separated precipitate was filtered off and recrystallized from ethanol.
3-(2,6-Dichlorophenyl)-1-(1,2,3,4-tetrahydronaphthalen-6-yl)prop-2-en-1-ones (3a): IR: 1690 (C=O), 1650 (C=C). 1H-NMR (DMSO-d6): δ 1.7-1.73 (m, 4H, tetralin CH2), 2.76-2.8 (m, 4H, tetralin CH2), 7.21 (d, 1H, CH=, J = 10.4 Hz), 7.54 (d, 1H, CH=, J = 10.4 Hz), 7.37-7.8 (m, 6H, Ar-H). 13C-NMR: δ 22 (tetralin CH2), 29 (tetralin CH2), 125.5 (CH=), 143.2 (CH=), 129.01, 129.25, 130.59, 130.83, 132.11, 134.37, 134.3, 135.07, 136.2, 137.3 (Ar-C), 188.5 (C=O). MS, m/z (rel. int.): 334 (M+, 0.3), 176 (50), 175 (75), 173 (100), 138 (5).
3-(2,6-Difluorophenyl)-1-(1,2,3,4-tetrahydronaphthalen-6-yl)prop-2-en-1-ones (3b): IR: 1651 (C=O), 1548 (C=C), 1H-NMR (DMSO-d6): δ 1.7 (m, 4H, tetralin CH2), 2.5 (m, 4H, tetralin CH2), 7.24 (d, 1H, CH=, J = 8.3 Hz), 7.84 (d, 1H, CH=, J = 8.3 Hz), 6.66-7.6 (m, 6H, Ar-H); 13C-NMR: δ 22 (tetralin CH2), 29 (tetralin CH2), 129.3 (CH=), 136.6 (CH=), 111.2, 112.3, 126.7, 129.9, 131.16, 134.26, 134.3, 135.9, 142.5, 157.3 (Ar-C), 186.9 (C=O). MS, m/z (rel. int.): 298 (M+, 0.2), 165 (19), 139 (2), 137 (100), 131 (3), 75 (5).
3-(3-Ethoxy-4-hydroxyphenyl))-1-(1,2,3,4-tetrahydronaphthalen-6-yl)prop-2-en-1-ones (3c): IR: 3420 (OH), 1634 (C=O) 1539 (C=C). 1H-NMR: δ 1.35 (t, 3H, CH3, J = 7.1 Hz), 1.70-1.73 (m, 4H, tetralin CH2), 2.5 (m, 4H, tetralin CH2), 4.08 (q, 2H, CH2, J = 11.05 Hz), 7.15 (d, 1H, CH=, J = 9.4 Hz), 7.40 (d, 1H, CH=, J = 9.4 Hz), 6.97-7.4 (m, 6H, Ar-H), 9.75 (s, 1H, OH). 13C-NMR: δ 14.49 (CH3), 22.2 (tetralin CH2), 28.8 (tetralin CH2), 125.7 (CH=), 147.2 (CH=), 111.8, 113.3, 115.6, 123.7, 126.2, 128.4, 129.8, 136.7, 137.01, 141.9, 149.8, 153.2 (Ar-C), 188.56 (C=O). MS, m/z (rel. int.): 174 (30), 166 (67), 159 (100), 137 (100), 131 (17).

3.3. 1-Acetyl-4-(2,6-difluorophenyl)-3-(1,2,3,4-tetrahydronaphthalen-6-yl)-2-pyrazoline 4

Hydrazine hydrate (99%, 1.0 mL) was added to a solution of compound 3b (2.98 g, 0.01 mol) in acetic acid (30 mL) and the mixture was heated under reflux for 6 h. and the excess solvent was distilled in vacuo. Cold water (30 mL) was then added to the remaining residue and the separated crude product was filtered, washed with water, dried and crystallized from acetic acid. IR: 2880-2910 (tetralin CH2 & CH3), 1710 (C=O). 1H-NMR (DMSO-d6): δ 1.76-1.87 (m, 4H, tetralin CH2), 4.1 (dd, 2H, pyrazoline CH2, J = 14.2 Hz), 2.15 (s, 3H, CH3), 2.75-2.8 (m, 4H, tetralin CH2), 6.5-6.9 (m, 1H, pyrazoline CH), 7.0-7.5 (m, 6H, Ar-H). 13C-NMR: δ 22.3 (tetralin CH2), 24.4 (CH3), 28.92 (tetralin CH2), 38.67 (pyrazoline CH2), 39.67 (pyrazoline CH), 111.8, 123.7, 126.2, 128.4, 129.8, 136.7, 137.01, 149.8, 141.9, 153.2 (Ar-C), 157.3 (imine C), 168.2 (C=O). MS m/z (rel. int.): 169 (72), 141 (40), 116 (20), 96 (46), 74 (100).

3.4. 4-Aryl-6-(1,2,3,4-tetrahydronaphthalen-6-yl)-1,2-dihydropyrimidine-2-thiones 5a,b

A solution of potassium hydroxide (1.7 g, 0.03 mol) in water (4 mL) was added to a mixture of the appropriate α,β-unsaturated ketone 3a,b (0.01 mol) and thiourea (0.9 g, 0.012 mol), in ethanol (50 mL) and the mixture was heated under reflux for 24 h. The excess of solvent was then distilled off and the residue was acidified with dilute hydrochloric acid. The separated crude product was filtered, washed with water, dried and crystallized from aqueous ethanol.
4-(2,6-Dichlorophenyl)-6-(1,2,3,4-tetrahydronaphthalen-6-yl)-1,2-dihydropyrimidine-2-thione (5a): IR: 3400 (NH), 2888-2921 (tetralin CH2), 1050 (C=S). 1H-NMR (DMSO-d6): δ 1.67-1.7 (m, 4H, tetralin CH2), 2.49-2.52 (m, 4H, tetralin CH2), 3.55 (s, 1H, NH), 5.5 (s, 1H, pyrimidine CH), 6.6-7.1 (m, 6H, Ar-H). MS, m/z (rel. int.): 159 (100), 131 (19), 91 (40), 78 (60).
4-(2,6-Difluorophenyl)-6-(1,2,3,4-tetrahydronaphthalen-6-yl)-1,2-dihydropyrimidine-2-thione (5b): IR: 3400 (NH), 2880-2925 (tetralin CH2), 1050 (C=S). 1H-NMR (DMSO-d6): δ 1.65-1.66 (m, 4H, tetralin CH2), 2.4-2.5 (m, 4H, tetralin CH2), 3.5 (s, 1H, NH), 5.5 (s, 1H, pyrimidine CH), 6.57-7.14 (m, 6H, Ar-H). 13C-NMR: δ 22 (tetralin CH2), 29 (tetralin CH2), 104 (pyrimidine CH), 105.5, 111.2, 126.7, 129.6, 131.16, 134.26, 134.3, 135.9, 142.5, 157.3 (Ar-C), 185 (C=S). MS, m/z (rel. int.): 131 (8), 113 (2), 112 (4), 96 (31), 76 (7).

3.5. 4-Aryl-6-(1,2,3,4-tetrahydronaphthalen-6-yl)-2-oxo-1,2-dihydropyridine-3-carbonitriles 6a,b

A mixture of 6-acetyltetraline 1 (1.74 g, 0.01 mol), ethyl cyanoacetate (1.13 g, 0.01 mol), the appropriate aldehyde 2a,b, and ammonium acetate (6.0 g), was heated in n-butanol (40 mL) under reflux for 3 h. On cooling, the separated yellow solid was filtered, washed with water and crystallized.
4-(2,6-Dichlorophenyl)-6-(1,2,3,4-tetrahydronaphthalen-6-yl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (6a): IR: 3330 (NH), 2987-2910 (tetralin CH2), 2228 (CN), 1616 (C=O). 1H-NMR (CDCl3): δ 1.79-1.82 (m, 4H, tetralin CH2), 2.76-2.82 (m, 4H, tetralin CH2), 7.25-7.48 (m, 7H, Ar-H), 7.75 (s, 1H, NH). 13C-NMR: δ 22 (tetralin CH2), 28 (tetralin CH2), 114.4 (CN), 105.5, 123.5, 127.4, 127.7, 130.4, 132.7, 133.7, 127.8, 129.5, 138.4, 141.6, 151.5, 156.4, 165.5 (Ar-C & pyridine-C), 162.69 (C=O). MS, m/z (rel. int.): 398 (M+, 0.7), 205 (100), 174 (4), 148 (3), 131 (11), 91 (20), 65 (3).
4-(2,6-Difluorophenyl)-6-(1,2,3,4-tetrahydronaphthalen-6-yl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (6b): IR: 3430 (NH), 2990-2995 (tetralin CH2), 2217 (CN), 1600 (C=O). 1H-NMR (CDCl3): δ 1.75-1.82 (m, 4H, tetralin CH2), 2.76-2.81 (m, 4H, tetralin CH2), 6.8-7.2 (m, 7H, Ar-H), 7.61 (s, 1H, NH). MS, m/z (rel. int.): 362 (M+, 0.5), 174 (26), 166 (100), 159 (100), 131 (4), 118 (5).

3.6. 4-Aryl-6-(1,2,3,4-tetrahydronaphthalen-6-yl)-2-thioxo-1,2-dihydropyridine-3-carbonitriles 7a-c

A mixture of 6-acetyltetraline 1 (1.74 g, 0.01 mol), 2-cyanothioacetamide (1 g, 0.01 mol), the appropriate aldehyde 2a-b, and ammonium acetate (6.0 g), was heated under reflux in n-butanol (40 mL) for 3 h. On cooling, the separated yellow solid was filtered, washed with water and crystallized.
4-(2,6-Dichlorophenyl)-6-(1,2,3,4-tetrahydronaphthalen-6-yl)-2-thioxo-1,2-dihydropyridine-3-carbonitrile (7a): IR: 3450 (NH), 2988-2995 (tetralin CH2), 2240 (CN), 1340 & 1140 (C=S). 1H-NMR (DMSO-d6): δ 1.8-1.82 (m, 4H, tetralin CH2), 2.77-2.81 (m, 4H, tetralin CH2), 6.5 (s, 1H, NH), 7.2-7.6 (m, 7H, Ar-H & pyridine-H). 13C-NMR: δ 22 (tetralin CH2), 30 (tetralin CH2), 115.5 (CN), 105, 123.5, 127.4, 127.7, 130.4, 132.7, 133.7, 127.8, 129.5, 138.4, 141.6, 105.5, 151.5, 156.4 (Ar-C & pyridine-C), 164 (C=S). MS, m/z (rel. int.): 281 (20), 207 (35), 147 (23), 135 (32).
4-(2,6-Difluorophenyl)-6-(1,2,3,4-tetrahydronaphthalen-6-yl)-2-thioxo-1,2-dihydropyridine-3-carbonitrile (7b): IR: 3450 (NH), 2910-2985 (tetralin CH2), 2240 (CN), 1310 & 1090 (C=S). 1H-NMR (DMSO-d6): δ 1.73-1.8 (m, 4H, tetralin CH2), 2.74-2.8 (m, 4H, tetralin CH2), 5.18 (s, 1H, NH), 7.15-7.82 (m, 7H, Ar-H & pyridine-H). MS, m/z (rel. int.): 378 (M+, 2.7), 361 (2), 207 (16), 159 (29), 78 (75).
4-(3-Ethoxy-4-hydroxyphenyl)-6-(1,2,3,4-tetrahydronaphthalen-6-yl)-2-thioxo-1,2-dihydropyridine-3-carbonitrile (7c): IR: 3470 (NH), 3310 (OH), 2820-2995 (tetralin CH2, CH3, CH2), 2250 (CN), 1310 & 1110 (C=S). 1H-NMR (DMSO-d6): δ 1.33-1.35 (t, 3H, CH3, J = 2.93 Hz), 1.73-1.8 (m, 4H, tetralin CH2), 2.76-2.8 (m, 4H, tetralin CH2), 4.11 (q, 2H, CH2CH3, J = 2.93 Hz), 9.7 (s, 1H, NH), 7.0-7.6 (m, 7H, Ar-H & pyridine-H). 13C-NMR: δ 15.5 (CH3), 22 (tetralin CH2), 30 (tetralin CH2), 58.5 (CH2CH3), 115.5 (CN), 102.5, 104.0, 110.5, 129.4, 133.7, 135.4, 138.7, 140.7, 127.8, 128.5, 142.4, 145.6, 105.5, 153.5, 158.4, 166.5 (Ar-C & pyridine-C), 168 (C=S). MS, m/z (rel. int.): 174 (33), 159 (100), 131 (20), 104 (2).

3.7. 4-Aryl-6-(1,2,3,4-tetrahydronaphthalen-6-yl)-2-imino-1,2-dihydropyridine-3-carbonitriles 8a,b

A mixture of 6-acetyltetraline 1 (1.74 g, 0.01 mol), malononitrile (0.66 g, 0.01 mol), the appropriate aldehyde 2a-b, and ammonium acetate (6.0 g), was heated under reflux in n-butanol (40 mL) for 3 h. On cooling, the separated yellow solid was filtered, washed with water and crystallized.
4-(2,6-Dichlorophenyl)-6-(1,2,3,4-tetrahydronaphthalen-6-yl)-2-imino-1,2-dihydropyridine-3-carbonitrile (8a): IR: 3500, 3450 (NH), 2820-2995 (tetralin CH2), 2250 (CN). 1H-NMR (CDCl3): δ 1.79-1.82 (m, 4H, tetralin CH2), 2.1 (s, 1H, NH), 2.81-2.83 (m, 4H, tetralin CH2), 5.61 (s, 1H, NH), 7-7.6 (m, 7H, Ar-H & pyridine-H). 13C-NMR: δ 22.2 (tetralin CH2), 28.7 (tetralin CH2), 114.9 (CN), 104.0 123.7, 127.4, 127.6, 128.8, 130.01, 133.2, 136.8, 149.9, 159.06, 110.9, 128.6, 159.9, 162.0, 166.5 (Ar-C & pyridine-C), 176.06 (C=NH). MS, m/z (rel. int.): 207 (100), 159 (98), 151 (8), 131 (15), 119 (3).
4-(2,6-Difluorophenyl)-6-(1,2,3,4-tetrahydronaphthalen-6-yl)-2-imino-1,2-dihydropyridine-3-carbonitrile (8b): IR: 3470, 3450 (NH), 2820-2990 (tetralin CH2), 2250 (CN). 1H-NMR (CDCl3): δ 1.81-1.826 (m, 4H, tetralin CH2), 2.1 (s, 1H, NH), 2.81-2.83 (m, 4H, tetralin CH2), 5.61 (s, 1H, NH), 6.9-7.67 (m, 7H, Ar-H & pyridine-H). 13C-NMR: δ 22.36 (tetralin CH2), 28.91 (tetralin CH2), 115.8 (CN), 104.5, 111.37, 111.68, 112.14, 123.98, 127.64, 129.15, 129.54, 131.03, 131.12, 137.23, 155.5, 1157.6, 161.3, 166.6 (Ar-C & pyridine-C), 174.1 (C=NH). MS, m/z (rel. int.): 194 (5), 131 (100), 127 (100), 104 (100).

3.8. Determination of the anticancer activity [26]

Cell monolayers were fixed with 10% (w/v) trichloroacetic acid and stained for 30 minutes with 0.4% (wt/vol) sulforhodamine B (SRB) dissolved in 1% acetic acid. Unbound dye was removed by four washes with 1% acetic acid, and protein-bound dye was extracted with 10 mM unbuffered Tris base [tris (hydroxymethyl) aminomethane] for determination of optical density in a computer-interfaced, 96-well microtiter plate reader at 510 nm.

4. Conclusions

New tetrahydronaphthaline derivatives bearing different heterocyclic moieties were tested for in vitro antitumor activity. The results indicated that the 2,6-dihaloarylchalcone derivatives 3a,b, the cyanopyridone derivatives 6a,b and thioxopyridine derivatives 7a-c were the most effective against the cervix cell line (Hela), showing IC50 values of 3.5, 10.5, 7.1, 10.9, 8.1, 5.9 and 6.5 μg/mL, respectively. All the tested compounds showed moderate to marginal activity against the breast carcinoma cell line MCF-7. Compound 3a was the most potent, with an IC50 value of 3.5 μg/mL against Hela and 4.5 μg/mL against MCF7 cell line. Compound 3a seems a promising new lead compound with a novel skeleton for further development towards a new potential clinical trials candidate.

Acknowledgements

The author would like to thank Abdelhamid Emwas, King Abdullah University for Science and Technology, Jeddah, Saudi Arabia, for recording the NMR spectra.

References

  1. Balunas, M.J.; Kinghorn, A.D. Drug Discovery from medicinal plants. Life Sci. 2005, 78, 431–441. [Google Scholar] [CrossRef] [PubMed]
  2. Parkin, D.M. Global cancer statistics in the year 2000. Lancet Oncol. 2001, 2, 533–543. [Google Scholar] [CrossRef]
  3. Carmen, A.J.; Carlos, M. Medicinal Chemistry of Anticancer Drugs, 1st ed.; Elsevier: Amsterdam, The Netherlands, 2008; pp. 1–8. [Google Scholar]
  4. Ferrante, A.; Augliera, J.; Lewis, K. Cloning of an organic solvent-resistance gene in Escherichia coli: The unexpected role of alkylhydroperoxide reductase. Proc. Natl. Acad. Sci. USA 1995, 92, 7617–7621. [Google Scholar] [CrossRef] [PubMed]
  5. Hara, H.; Fujihashi, T.; Sakata, T. Tetrahydronaphthalene lignan compounds as potent anti-HIV type 1 agents. AIDS Res. Hum. Retroviruses 1997, 13, 695–705. [Google Scholar] [CrossRef] [PubMed]
  6. Ebeid, M.Y.; El-Zahar, M.I.; Kamel, M.M.; Omar, M.T.; Anwar, M.M. Novel 5,6,7,8-tetrahydronaphth-2-ylheterocycles of possible biological activity. Egypt. Pharm. J. NRC 2004, 3, 49–65. [Google Scholar]
  7. Nabih, I.; Zayed, A.; Kamel, M.M.; Motawie, M.S. Synthesis of new tetrahydronaphthyl-1,2,4-triazines of potensial antimicrobial activity. Egypt. J. Chem. 1986, 29, 101–106. [Google Scholar]
  8. Hussain, R.A.; Dickey, J.K.; Rosser, M.P.; Matson, J.A.; Kozlowski, M.R.; Brittain, R.J.; Webb, M.L.; Rose, P.M.; Fernandes, P.A. Novel class of non-peptidic endothelin antagonists isolated from the medicinal herb phyllanthus niruri. J. Nat. Prod. 1995, 58, 1515–1520. [Google Scholar] [CrossRef]
  9. Chalina, E.G.; Chakarova, L. Synthesis, hypotensive and antiarrhythmic activities of 3-alkyl-1-(2-hydroxy-5,8-dimethoxy-1,2,3,4-tetrahydro-3-naphthalenyl)ureas or thioureas and their guanidine analogues. Eur. J. Med. Chem. 1998, 33, 975–983. [Google Scholar] [CrossRef]
  10. Kamel, M.M.; Michael, J.M. Synthesis and moulscicidal activity of some salicylamido tetralins. Egypt. J. Bilharziasis 1988, 10, 121–125. [Google Scholar]
  11. Cimetière, B.; Dubuffet, T.; Muller, O.; Descombes, J.; Simonet, S.; Laubie, M.; Verbeuren, T.J.; Lavielle, G. Synthesis and biological evaluation of new tetrahydronaphthalene derivatives as thromboxane receptor antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 1375–1340. [Google Scholar] [CrossRef]
  12. Takami, M.; Tsukada, W. Effect of DP-1904, a thromboxane synthetase inhibitor, on antigen- and spasmogen-induced bronchoconstriction in rodents. Eur. J. Pharmacol. 1999, 366, 253–259. [Google Scholar] [CrossRef]
  13. Rogóz, Z.; Skuza, G.; Kodziñska, A. Anxiolytic-and antidepressant-like effects of 7-OH DPAT, preferential dopamine D3 receptor agonist in rats. Pol. J. Pharmacol. 2004, 56, 519–529. [Google Scholar]
  14. Kitamura, Y.; Araki, H.; Shibata, K.; Gomita, Y.; Tanizaki, Y. 5-HT1A receptor full agonist, 8-OH-DPAT, exerts antidepressant-like effects in the forced swim test in ACTH-treated rats. Eur. J. Pharmacol. 2003, 481, 75–77. [Google Scholar] [CrossRef] [PubMed]
  15. Amin, K.M.; El-Zahar, M.I.; Anwar, M.; Kamel, M.; Mohamad, M. Synthesis and anticancer activity of novel tetralin-6-yl pyridine and tetralin-6-yl pyrimidine derivatives. Acta Pol. Pharm. 2009, 66, 279–291. [Google Scholar] [PubMed]
  16. Dong, Y.Z.; Shi, Q.; Nakagawa-Goto, K.; Wu, P.C.; Bastow, K.F.; Morris-Natschke, S.L.; Lee, K.H. Antitumor agents 269. Non-aromatic ring-A neotanshinlactone analog, TNO, as a new class of potent antitumor agents. Bioorg. Med. Chem. Lett. 2009, 19, 6289–6292. [Google Scholar] [CrossRef] [PubMed]
  17. Öztürk, G.; Erol, D.D.; Uzbay, T.; Aytemir, M.D. Synthesis of 4(1H)-pyridinone derivatives and investigation of analgesic and antiinflammatory activities. Farmaco 2001, 56, 251–256. [Google Scholar] [CrossRef]
  18. Findlay, J.A.; Tam, W.H.J.; Krepinsky, J. The chemistry of some 6-methyl-4-hydroxy-2-pyridones. Can. J. Chem. 1978, 56, 613–616. [Google Scholar] [CrossRef]
  19. Abadi, A.; Al-Deeb, O.; Al-Afify, A.; El-Kashef, H. Synthesis of 4-alkyl (aryl)-6-aryl-3-cyano-2(1H)-pyridinones and their 2-imino isosteres as nonsteroidal cardiotonic agents. Farmaco 1999, 54, 195–201. [Google Scholar] [CrossRef]
  20. Storck, P.; Aubertin, A.; Grierson, D.S. Tosylation/mesylation of 4-hydroxy-3-nitro-2-pyridinones as an activation step in the construction of dihydropyrido[3,4-b] benzo[f][1,4]thiazepin-1-one based anti-HIV agents. Tetrahedron Lett. 2005, 46, 2919–2922. [Google Scholar] [CrossRef]
  21. Macdonald, G.E.; Puri, A.; Shilling, D.G. Interactive effect of photoperiod and fluridone on growth, reproduction, and biochemistry of dioecious hydrilla (Hydrilla Verticillata). Weed Sci. 2008, 56, 189–195. [Google Scholar] [CrossRef]
  22. Evidente, A.; Fiore, M.; Bruno, G.; Sparapano, L.; Motta, A. Chemical and biological characterisation of sapinopyridione, a phytotoxic 3,3,6-trisubstituted-2,4-pyridione produced by Sphaeropsis sapinea, a toxigenic pathogen of native and exotic conifers, and its derivatives. Phytochemistry 2006, 67, 1019–1028. [Google Scholar] [CrossRef] [PubMed]
  23. Cocco, M.T.; Congiu, C.; Onnis, V. Synthesis and antitumour activity of 4-hydroxy-2-pyridone derivatives. Eur. J. Med. Chem. 2000, 35, 545–552. [Google Scholar] [CrossRef]
  24. Cocco, M.T.; Congiu, C.; Onnis, V. New bis(pyridyl)methane derivatives from 4-hydroxy-2-pyridones: synthesis and antitumoral activity. Eur. J. Med. Chem. 2003, 38, 37–47. [Google Scholar] [CrossRef]
  25. Allinger, N.L.; Jones, E.S. Synthesis of some functionally substituted benzocyclanones. J. Org. Chem. 1962, 27, 70–76. [Google Scholar] [CrossRef]
  26. Storeng, P.; Ritsa, S.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.T.; Bokesch, H.; Kenney, S.; Boyd, M.R. Anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107–1112. [Google Scholar]
  27. Ghoshal, K.; Jacob, S.T. An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem. Pharmacol. 1997, 53, 1569–1575. [Google Scholar] [CrossRef]
Sample Availability: Contact the author.
Molecules 16 03410 sch001 550
Scheme 1. Synthetic pathways to compounds 3a-c, 4 and 5a,b.
Scheme 1. Synthetic pathways to compounds 3a-c, 4 and 5a,b.
Molecules 16 03410 sch001
Molecules 16 03410 sch002 550
Scheme 2. Synthetic pathways of compounds 6a,b, 7a-c and 8a,b.
Scheme 2. Synthetic pathways of compounds 6a,b, 7a-c and 8a,b.
Molecules 16 03410 sch002
Table
Table 1. Melting points, crystallization solvents, yields, molecular formulae and molecular weights of newly synthesized compounds 3a-c, 4, 5a,b, 6a,b, 7a-c and 8a,b.
Table 1. Melting points, crystallization solvents, yields, molecular formulae and molecular weights of newly synthesized compounds 3a-c, 4, 5a,b, 6a,b, 7a-c and 8a,b.
Comp. No.XMp (ºC)Cryst. Solv.Yield (%)Molecular Formula (Mol. Wt.)
3a2,6-Cl271-3EtOH53C19H16Cl2O (331.24)
3b2,6-F2250-2EtOH42C19H16F2O (298.34)
3c3-EtO,4-OH77-9EtOH80C20H20O2 (292.38)
4-> 300AcOH95C21H20F2N2O (354.40)
5a2,6-Cl2> 300EtOH/H2O20C20H16Cl2 N2S (387.33)
5b2,6-F2253-5EtOH/H2O28C20H16F2 N2S (354.42)
6a2,6-Cl2252-4AcOH18C22H16Cl2 N2O (395.29)
6b2,6-F2250-2AcOH30C22H16F2 N2O (362.38)
7a2,6-Cl2150-2AcOH25C22H16Cl2 N2S (411.36)
7b2,6-F2124-6AcOH53C22H16F2 N2S (378.45)
7c3-EtO-4-OH226-8AcOH90C23H20 N2OS (372.49)
8a2,6-Cl2193-5AcOH26C22H17Cl2 N3 (394.31)
8b2,6-F2100-2AcOH34C22H17F2 N3 (361.40)
Table
Table 2. Effect of compounds 3a-c, 4, 5a,b, 6a,b, 7a-c and 8a,b on cervix carcinoma cell line (Hela) and breast carcinoma cell line (MCF7).
Table 2. Effect of compounds 3a-c, 4, 5a,b, 6a,b, 7a-c and 8a,b on cervix carcinoma cell line (Hela) and breast carcinoma cell line (MCF7).
Compound No.IC50(μg/mL)
HelaMCF7
3a3.54.5
3b10.515
3c12.518.3
411.319
5a10.720.5
5b11.917.3
6a7.112
6b10.917.5
7a8.116
7b5.912.5
7c6.516
8a12.122.3
8b12.121.7
5-FU-3.5

Share and Cite

MDPI and ACS Style

Al-Abdullah, E.S. Synthesis and Anticancer Activity of Some Novel Tetralin-6-yl-pyrazoline, 2-Thioxopyrimidine, 2-Oxopyridine, 2-Thioxo-pyridine and 2-Iminopyridine Derivatives. Molecules 2011, 16, 3410-3419. https://doi.org/10.3390/molecules16043410

AMA Style

Al-Abdullah ES. Synthesis and Anticancer Activity of Some Novel Tetralin-6-yl-pyrazoline, 2-Thioxopyrimidine, 2-Oxopyridine, 2-Thioxo-pyridine and 2-Iminopyridine Derivatives. Molecules. 2011; 16(4):3410-3419. https://doi.org/10.3390/molecules16043410

Chicago/Turabian Style

Al-Abdullah, Ebtehal S. 2011. "Synthesis and Anticancer Activity of Some Novel Tetralin-6-yl-pyrazoline, 2-Thioxopyrimidine, 2-Oxopyridine, 2-Thioxo-pyridine and 2-Iminopyridine Derivatives" Molecules 16, no. 4: 3410-3419. https://doi.org/10.3390/molecules16043410

APA Style

Al-Abdullah, E. S. (2011). Synthesis and Anticancer Activity of Some Novel Tetralin-6-yl-pyrazoline, 2-Thioxopyrimidine, 2-Oxopyridine, 2-Thioxo-pyridine and 2-Iminopyridine Derivatives. Molecules, 16(4), 3410-3419. https://doi.org/10.3390/molecules16043410

Article Metrics

Back to TopTop